Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PHI-101, an orally active FLT3 inhibitor, effectively overcomes resistance associated with numerous drug-resistant mutations. It potently suppresses both single activating FLT3 mutations (ITD or TKD mutants) and inhibits double (ITD/D835Y or ITD/F691L) as well as triple (ITD/D835Y/F691L) resistance mutations. This compound shows promise for investigation in the context of relapsed or refractory acute myeloid leukemia (AML) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PHI-101, an orally active FLT3 inhibitor, effectively overcomes resistance associated with numerous drug-resistant mutations. It potently suppresses both single activating FLT3 mutations (ITD or TKD mutants) and inhibits double (ITD/D835Y or ITD/F691L) as well as triple (ITD/D835Y/F691L) resistance mutations. This compound shows promise for investigation in the context of relapsed or refractory acute myeloid leukemia (AML) [1]. |
Molecular Weight | 386.44 |
Formula | C19H19FN4O2S |
CAS No. | 2127107-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PHI-101 2127107-15-5 inhibitor inhibit